What’s Next For Novo Nordisk Stock?

Novo Nordisk’s stock fell 16% on February 23rd after clinical trial results showed that its experimental weight-loss pill, CagriSema, underperformed relative to Eli Lilly’s competing drug, Mounjaro. The trial data revealed that CagriSema achieved lower weight reduction outcomes than Lilly’s GLP-1 therapy, a meaningful blow given that the obesity drug race is increasingly winner-takes-most. This single-day drop now brings NVO’s twelve-month return to -56%. The obvious question: Is this a buying opportunity? We don’t think so.

But, before we delve into the details, if you seek an upside with less volatility than holding an individual stock like NVO, consider the High Quality Portfolio. It has comfortably outperformed its benchmark – a combination of the S&P 500, Russell, and S&P MidCap indexes – and has achieved returns exceeding 105% since its inception. Why is that? As a group, HQ Portfolio stocks provided better returns with less risk versus the benchmark index; less of a roller-coaster ride, as evident in HQ Portfolio performance metrics. On a separate note, see – Ethereum Solved Its Scaling Problem. That’s the Problem.

Photo by Memed_Nurrohmad on Pixabay

Let’s start with the fundamentals

Novo Nordisk’s revenue grew 11% over the last twelve months to $46.9 billion – respectable in isolation, but a sharp deceleration from the three-year average growth rate of 24%. Margins tell a similar story. Operating profit margin sits at 41.3%, down from a three-year average of 43.2%, and operating cash flow margin has slipped to 39% from 42%. So the business is still highly profitable, but the trajectory is moving in the wrong direction on both growth and margins simultaneously. That matters.

The balance sheet, to its credit, remains solid. Debt-to-equity stands at 11% – elevated relative to prior levels largely because the falling stock price has compressed the equity base, not because the company has been reckless with borrowing. Cash as a percentage of assets is around 5%, which is lean but manageable for a company generating cash at this scale. No red flags here.

Is the valuation attractive enough?

At roughly $40 per share, NVO trades at 11x trailing earnings of $3.49 – well below its three-year average of 26x, and cheaper than peers like LLY, ABBV, and JNJ. On the surface, that looks compelling. But valuation alone is rarely sufficient reason to buy a stock, and this is a case where the multiple compression is telling you something important: the market is reassessing the long-term earnings power of the business, not just being irrationally pessimistic.

The premium NVO commanded was built on the expectation that it would be a dominant, perhaps co-dominant, player in the GLP-1 weight loss market. That thesis is now under pressure. Wall Street analysts have already begun lowering their ratings, citing a long-term clinical edge in favor of Eli Lilly. The average analyst price target of $57 will likely face downward revisions – meaning the apparent upside in that number is probably overstated right now.

So, should you buy the dip?

We don’t think so. At least not yet. Yes, the stock is cheap relative to its own history. And yes, a -56% drawdown over twelve months is dramatic. But the core risk here isn’t valuation; it’s narrative. When a company loses its clinical edge in the market that drove its premium, the re-rating process rarely ends in a single day. Negative sentiment tends to persist until there’s a concrete catalyst to reverse it – new trial data, a partnership, or a competitive surprise – none of which are visible on the horizon right now.

Could we be wrong? Absolutely. Stocks that have fallen this far can rebound sharply on even marginally better news, and NVO’s underlying business, with $46.9 billion in revenue and 41% operating margins, is far from broken. Investors with a long time horizon and high risk tolerance might find the current price defensible as a small position.

But from a pure risk-reward standpoint, if the thesis is exposure to the weight loss drug space, LLY remains the stronger play. Its clinical lead is now more established, and while its valuation is far from cheap, you’re paying for a clearer path to dominance. In a winner-takes-most market, that clarity is worth a premium.

The Best Investors Think In Portfolios

Individual stocks like NVO are unpredictable. A smart portfolio helps you invest, limits downside shocks, and provides upside exposure. The Trefis High Quality (HQ) Portfolio, with a collection of 30 stocks, has a track record of comfortably outperforming its benchmark that includes all 3 – the S&P 500, S&P mid-cap, and Russell 2000 indices. Why is that? HQ Portfolio has posted more than 105% in cumulative return since inception, with less risk versus the benchmark index, as evident in HQ Portfolio performance metrics.

Invest with Trefis Market-Beating Portfolios
See all Trefis Price Estimates